The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Optimising Pharmaceutical Care For People With Dementia In Acute Care Settings
Funder
National Health and Medical Research Council
Funding Amount
$719,637.00
Summary
Delivering appropriate acute care services for people with dementia is a major healthcare challenge in Australia. People with dementia do not receive appropriate care in hospitals and are more likely to experience worse clinical outcomes compared to people without dementia. This proposal will establish the first large-scale multi-centre cohort of inpatients with dementia, to systematically investigate the impact of hospitalisation on prescribing, clinical and patient-centred outcomes.
Novel Octapeptin Antibiotics Targeting Extremely Drug Resistant 'superbugs'
Funder
National Health and Medical Research Council
Funding Amount
$946,024.00
Summary
The World Health Organization (WHO) has identified antimicrobial resistance as one of the three greatest threats to human health. Many clinicians worldwide have already been confronted with the reality of infections caused by extremely drug resistant (XDR) bacterial 'superbugs' resistant to all available antibiotics. This project aims to develop safe and efficacious octapeptin antibiotics for the treatment of life-threatening infections caused by problematic XDR ‘superbugs'.
Targeting The Metastasis Suppressor NDRG1 For The Treatment Of Pancreatic Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$327,142.00
Summary
We will investigate NDRG1, a novel molecular target that has been demonstrated to inhibit the progression of numerous cancers. We aim to better understand the underlying functions of NDRG1 in pancreatic cancer and how we can potentially target this gene with novel therapeutics being developed in our laboratory. We hope that this new approach will lead to more promising treatment options and a better outcome for those suffering from pancreatic cancer.
Influence Of Skin Cancer On Topical Elongate Microparticle Drug Delivery
Funder
National Health and Medical Research Council
Funding Amount
$560,589.00
Summary
This project builds on a novel cutaneous delivery method using ‘rod-shaped’ microparticles we developed in the Dermatology Research Centre. Microparticle administration results in multiple punctures of the skin’s tough outer layers, increasing permeability. Furthermore, microparticle administration results in a uniform and continuous drug delivery profile within the treatment area, which is an important attribute for the treatment of skin diseases.
Optimisation Of The Safety And Efficacy Of Protein Kinase Inhibitors Using Endogenous And Dietary Biomarkers
Funder
National Health and Medical Research Council
Funding Amount
$384,360.00
Summary
Many new cancer medicines are part of the 'kinase inhibitor' group of drugs. Although these drugs are effective in treating a range of different cancers, opportunities remain to improve the effectiveness and safety by more intelligently deciding the dose of the drug that a specific individual should receive. The research aims to assess whether the levels of chemicals normally present in the blood of individuals being treated can be used to guide the best dose an individual should receive.
RCTs on Trial: How Placebo Effects Could Undermine Double-blind RCTs. Double-blind randomised placebo-controlled trials (RCTs) are considered the gold standard for establishing treatment efficacy. However, there are both theoretical and empirical reasons to believe that they do not adequately control for the placebo effect. Cost and ethical considerations prevent researchers conducting actual double-blind RCTs with patients from exploring these issues. To address this gap, this project uses nove ....RCTs on Trial: How Placebo Effects Could Undermine Double-blind RCTs. Double-blind randomised placebo-controlled trials (RCTs) are considered the gold standard for establishing treatment efficacy. However, there are both theoretical and empirical reasons to believe that they do not adequately control for the placebo effect. Cost and ethical considerations prevent researchers conducting actual double-blind RCTs with patients from exploring these issues. To address this gap, this project uses novel experimental models to systematically test key aspects of the double-blind RCT methodology that are intended to control for the placebo effect. The project aims to provide essential data on the validity of these trials, thereby improving Australia's health and ensuring that Government treatment subsidies are well spent.Read moreRead less
Centre For REdefining Antibiotic Use To ReDUce ResistanCE And Prolong The Lives Of Antibiotics (REDUCE)
Funder
National Health and Medical Research Council
Funding Amount
$2,158,296.00
Summary
Ineffective dosing of antimicrobials has contributed to the escalation of antimicrobial resistance which now pervades the healthcare system. Patients in the intensive care unit and post-transplant are examples of patients who commonly have infections, are more likely to fail treatment and have resistant microbes emerge. In these studies we will characterise the doses of antimicrobials that should be used in these difficult-to-treat patients and rapidly share these for routine clinical use.
Novel pharmacological agents to target stroke-induced brain injury. There is a looming stroke epidemic in Australia. 72% of Australian stroke sufferers are over the age of 65 and whereas in 1997 only 12% of Australians were in that age group, by 2030 that number will have increased to 23%. There is an urgent need for novel therapies. This project will aid the development of a novel anti-stroke therapy.
Improving The Therapeutic Use Of Anti-infective Agents: Application Of Pharmacometrics For Rational Dosing Regimen Design
Funder
National Health and Medical Research Council
Funding Amount
$313,390.00
Summary
There is no field of medicine in which the individualisation of medicines is more important than in infectious diseases – appropriate doses must be administered to maximise efficacy and to minimise side effects and the emergence of drug-resistance. This fellowship will use the emerging science of pharmacometrics to investigate factors contributing to the variability in response to anti-infective medications and to optimise dosing regimens for the best use of these drugs in clinical practice.
Advanced Imaging To Define Hepatic & Intestinal Drug Disposition In Aging & Liver Diseases
Funder
National Health and Medical Research Council
Funding Amount
$762,123.00
Summary
Aged people and liver disease patients have impaired drug absorption and elimination functions. Their response to drugs varies widely when given drug dosage regimens recommended for normal patients. This project will explore the possibility of using in vivo imaging techniques to define the gut and liver function and their response to administered drugs. This grant will help the selection of appropriate drugs and doses for aged people and patients with liver diseases, i.e. personalised medicine.